These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 24825748

  • 21. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [Abstract] [Full Text] [Related]

  • 22. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM, Chertin B, Fridmans A, Farkas A, Belanger A, Hartman H, Labrie F.
    Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
    [Abstract] [Full Text] [Related]

  • 23. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.
    Geller J.
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):28-35. PubMed ID: 3883502
    [Abstract] [Full Text] [Related]

  • 24. Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.
    Ferraldeschi R, Pezaro C, Karavasilis V, de Bono J.
    Annu Rev Med; 2013 Mar; 64():1-13. PubMed ID: 23020876
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
    Ueno S, Mizokami A, Fukagai T, Fujimoto N, Oh-Oka H, Kondo Y, Arai G, Ide H, Horie S, Ueki O, Kawaguchi K, Shimamura M, Orito M, Ishida T, Ikeda D, Namiki M.
    Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
    [Abstract] [Full Text] [Related]

  • 26. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG, Crawford ED, DeAntoni EP.
    Eur Urol; 1997 Sep; 32 Suppl 3():70-7. PubMed ID: 9267789
    [Abstract] [Full Text] [Related]

  • 27. Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
    Anderson J, Abrahamsson PA, Crawford D, Miller K, Tombal B.
    BJU Int; 2008 Jun; 101(12):1497-501. PubMed ID: 18336613
    [Abstract] [Full Text] [Related]

  • 28. Arguments for the long-term use of combined androgen blockade.
    Wajsman Z.
    Eur Urol; 1998 Jun; 34 Suppl 3():25-8. PubMed ID: 9854192
    [Abstract] [Full Text] [Related]

  • 29. Antiandrogens in the treatment of prostate cancer.
    Wirth MP, Hakenberg OW, Froehner M.
    Eur Urol; 2007 Feb; 51(2):306-13; discussion 314. PubMed ID: 17007995
    [Abstract] [Full Text] [Related]

  • 30. Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication.
    Qin X, Zhang H, Ye D, Yao X, Zhang S, Dai B.
    Andrology; 2013 May; 1(3):512-6. PubMed ID: 23536478
    [Abstract] [Full Text] [Related]

  • 31. Treatment of prostate cancer with gonadotropin-releasing hormone agonists.
    Labrie F, Dupont A, Bélanger A, St-Arnaud R, Giguère M, Lacourcière Y, Emond J, Monfette G.
    Endocr Rev; 1986 Feb; 7(1):67-74. PubMed ID: 3514203
    [Abstract] [Full Text] [Related]

  • 32. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
    Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F.
    J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
    [Abstract] [Full Text] [Related]

  • 33. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 34. Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease.
    Labrie F.
    Mol Cell Endocrinol; 2002 Dec 30; 198(1-2):77-87. PubMed ID: 12573817
    [Abstract] [Full Text] [Related]

  • 35. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep 30; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 36. Abiraterone acetate in castration-resistant prostate cancer.
    Iacovelli R, Palazzo A, Procopio G, Gazzaniga P, Cortesi E.
    Anticancer Drugs; 2012 Mar 30; 23(3):247-54. PubMed ID: 22123334
    [Abstract] [Full Text] [Related]

  • 37. Current status and prospects of androgen depletion therapy for prostate cancer.
    Akaza H.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr 30; 22(2):293-302. PubMed ID: 18471787
    [Abstract] [Full Text] [Related]

  • 38. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr 30; 22(2):229-41. PubMed ID: 18471782
    [Abstract] [Full Text] [Related]

  • 39. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
    Narimoto K, Mizokami A, Izumi K, Mihara S, Sawada K, Sugata T, Shimamura M, Miyazaki K, Nishino A, Namiki M.
    Int J Urol; 2010 Apr 30; 17(4):337-45. PubMed ID: 20202011
    [Abstract] [Full Text] [Related]

  • 40. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J.
    Eur Urol; 1997 Apr 30; 32 Suppl 3():78-80. PubMed ID: 9267790
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.